Andrea DiMartini

Andrea DiMartini

Auto-generated profile, based on publicly available information

Andrea DiMartini

Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2015 in Transplantation
Verified
Journal Article
Closed access
MDMary Amanda Dew
Mary Amanda Dew
EREmily M. Rosenberger
Emily M. Rosenberger
LMLarissa Myaskovsky
Larissa Myaskovsky
ADAndrea F. DiMartini
Andrea F. DiMartini
ADAnnette J. DeVito Dabbs
Annette J. DeVito Dabbs
JGJoel B. Greenhouse
Joel B. Greenhouse
Background Depression and anxiety are common mental health problems in transplant populations. There is mixed evidence concerning whether they increase morbidity and mortality risks after transplantation. If such associations exist, additional risk reduction strategies may be needed. Methods Four bibliographic databases were searched from 1981 through September 2014 for studies prospectively examining whether depression or anxiety (determined with diagnostic evaluations or standardized symptom scales) affected risk for posttransplant mortality, graft loss, acute graft rejection, chronic rejection, cancer, infection, and rehospitalization. Results Twenty-seven studies (10 heart, total n = 1738; 6 liver, n = 1063; 5 kidney, n = 49515; 4 lung, n = 584; 1 pancreas, n = 80; 1 mixed recipient sample, n = 205) were identified. In each, depression and/or anxiety were typically measured before or early after transplantation. Follow-up for outcomes was a median of 5.8 years (range, 0.50-18.0). Depression increased the relative risk (RR) of mortality by 65% (RR, 1.65; 95% confidence interval [95% CI], 1.34-2.05; 20 studies). Meta-regression indicated that risk was stronger in studies that did (vs did not) control for potential confounders (P = .032). Risk was unaffected by type of transplant or other study characteristics. Depression increased death-censored graft loss risk (RR, 1.65; 95% CI, 1.21-2.26, 3 studies). Depression was not associated with other morbidities (each morbidity was assessed in 1-4 studies). Anxiety did not significantly increase mortality risk (RR, 1.39; 95% CI, 0.85-2.27, 6 studies) or morbidity risks (assessed in single studies). Conclusions Depression increases risk for posttransplant mortality. Few studies considered morbidities; the depression-graft loss association suggests that linkages with morbidities deserve greater attention. Depression screening and treatment may be warranted, although whether these activities would reduce posttransplant mortality requires study.

9 March 2006 in Liver Transplantation
Verified
Journal Article
Open access
PDF file
ADAndrea DiMartini
Andrea DiMartini
NDNancy Day
Nancy Day
MDMary Amanda Dew
Mary Amanda Dew
LJLubna Javed
Lubna Javed
MFMary Grace Fitzgerald
Mary Grace Fitzgerald
PFPaulo Fontes
Paulo Fontes
For patients who receive a liver transplant (LTX) for alcoholic liver disease (ALD), investigators are focusing beyond survival to determine specific alcohol use outcomes. Studies suggest the use of alcohol ranges from 8 to 22% for the first post-transplant year with cumulative rates reaching 30 to 40% by 5 years following transplantation. Yet while investigators are interested in determining specific rates of alcohol use and predictors of use, only three studies since 1990 have been prospective. In 1998, we began a prospective study of post-LTX alcohol consumption in ALD recipients using multiple repeated measures of alcohol use. After 5 years of follow-up, we found that 22% had used any alcohol by the first year and 42% had a drink by 5 years. By 5 years, 26% drank at a heavier use (binge) pattern and 20% drank in a frequent pattern. In a univariate model, predictors of alcohol use included pre-transplant length of sobriety, a diagnosis of alcohol dependence, a history of other substance use, and prior alcohol rehabilitation. Liver Transpl 12:813–820, 2006. © 2006 AASLD.

20 August 2013 in Liver Transplantation
Verified
Journal Article
Open access
PDF file
ADAndrea DiMartini
Andrea DiMartini
RCRuy J. Cruz
Ruy J. Cruz
MDMary Amanda Dew
Mary Amanda Dew
LMLarissa Myaskovsky
Larissa Myaskovsky
BGBret Goodpaster
Bret Goodpaster
PFPaulo Fontes
Paulo Fontes
For patients with end-stage liver disease, commonly used indices of nutritional status (ie, body weight and body mass index) are often inflated because of fluid overload (ie, ascites and peripheral edema), and this results in an underdiagnosis of malnutrition. Because muscle is the largest protein reservoir in the body, an estimate of the muscle mass may be a more reliable and valid estimate of nutritional status. Therefore, we used pretransplant computed tomography data for 338 liver transplantation (LT) candidates to identify muscle and fat mass on the basis of a specific abdominal transverse section commonly used in body composition analyses, and we investigated the contribution of this measure to specific post-LT outcomes. We found that the majority of our patients (68%) could be defined as cachectic. For men, muscle mass predicted many important posttransplant outcomes, including intensive care unit (ICU) stay, total length of stay (LOS), and days of intubation. Muscle mass was a significant predictor of survival and also predicted disposition to home versus another facility. For women, muscle mass predicted ICU stay, total LOS, and days of intubation, but the effect was modest. Muscle mass did not predict survival or disposition for women. In conclusion, because pretransplant muscle mass is associated with many important postoperative outcomes, we discuss these findings in the context of possible pretransplant interventions for either improving or sustaining muscle mass before surgery. Liver Transpl 19:1172-1180, 2013. © 2013 AASLD.

19 August 2010 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
ADA. DiMartini
A. DiMartini
MDM. A. Dew
M. A. Dew
NDN. Day
N. Day
MFM. G. Fitzgerald
M. G. Fitzgerald
BJB. L. Jones
B. L. Jones
PFP. Fontes
P. Fontes
Any use of alcohol in the years following liver transplantation (LTX) approaches 50% of patients transplanted for alcoholic liver disease (ALD). We collected detailed prospective data on alcohol consumption following LTX for ALD to investigate ongoing patterns of use. Using trajectory modeling we identified four distinct alcohol use trajectories. One group had minimal use over time. Two other groups developed early onset moderate‐to‐heavy consumption and one group developed late onset moderate use. These trajectories demonstrate that alcohol use varies based on timing of onset, quantity and duration. Using discriminant function analysis, we examine characteristics of recipient's pre‐LTX alcohol histories and early post‐LTX psychological stressors to identify the profile of those at risk for these specific trajectories. We discuss the relevance of these findings to clinical care and preliminarily to outcomes.

1 June 2005 in Liver Transplantation
Verified
Journal Article
Closed access
PDF file
ADAndrea DiMartini
Andrea DiMartini
LJLubna Javed
Lubna Javed
SRSarah Russell
Sarah Russell
MDMary Amanda Dew
Mary Amanda Dew
MFMary Grace Fitzgerald
Mary Grace Fitzgerald
JFJohn Fung
John Fung

6 June 2011 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
ADA. DiMartini
A. DiMartini
MDM. A. Dew
M. A. Dew
DCD. Chaiffetz
D. Chaiffetz
MFM. G. Fitzgerald
M. G. Fitzgerald
MDM. E. Devera
M. E. Devera
PFP. Fontes
P. Fontes
Although it is well known that depression is associated with poorer medical outcomes, the association between depression- and liver transplant (LTX)-specific outcomes has not been investigated. We identified three trajectories of depressive symptoms evolving within the first post-LTX year in a cohort of 167 patients transplanted for alcoholic cirrhosis: a group with consistently low depression levels at all time points (group 1, n = 95), a group with initially low depression levels that rose over time (group 2, n = 41), and a group with consistently high depression levels (group 3, n = 31). Controlling for medical factors associated with poorer survival, recipients with increasing depression or persisting depression were more than twice as likely to die (all cause mortality) within the subsequent years. At 10 years post-LTX the survival rate was 66% for the low depression group, but only 46% and 43%, respectively, for the increasing depression and high depression groups. Except for a paradoxically higher percentage of malignancies in the low depression group, the causes of death and other specific LTX outcomes were not different between groups. Whether treatment of depression will improve survival rates is an area for research.